Information sur le cancer / Types de cancer / Neuroendocrinien / Recherche

Albanus DR, Apitzsch J, Erdem Z, et al. Clinical value of 68Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET). (2015, October). European Journal of Radiology. 84(10):1866-1872.

Balogova S, Talbot JN, Nataf V, et al. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. (2013, June). European Journal of Nuclear Medicine and Molecular Imaging. 40(6):943-966. Extrait de: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644207/.

Berruti A, Fazio N, Ferrero A, et al. Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study. (2014, March 14). BMC Cancer. 14:184. Extrait de: http://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-184.

Bodei L, Kidd M, Modlin IM, et al. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. (2016, May). European Journal of Nuclear Medicine and Molecular Imaging. 43(5):839-851.

Canadian Partnership Against Cancer. Canadian Cancer Trials. Extrait de: http://www.canadiancancertrials.ca.

Connolly HM, Schaff HV, Abel MD, et al. Early and late outcomes of surgical treatment in carcinoid heart disease. (2015, November 17). Journal of the American College of Cardiology. 66(20):2189-2196.

Demes M, Aszyk C, Bartsch H, Schirren J, Fisseler-Eckhoff A. Differential miRNA-expression as an adjunctive diagnostic tool in neuroendocrine tumors of the lung. (2016, March 25). Cancers. 8(4):38. Extrait de: http://www.mdpi.com/2072-6694/8/4/38.

Ducreux M, Dahan L, Smith D, et al. Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial): a phase II non-randomised trial. (2014, December). European Journal of Cancer. 50(18):3098-3106.

Hobday TJ, Qin R, Reidy-Lagunes D, et al. Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors. (2015, May 10). Journal of Clinical Oncology. 33(14):1551-1556.

Khan MS, Kirkwood AA, Tsigani T, et al. Early changes in circulating tumor cells are associated with response and survival following treatment of metastatic neuroendocrine neoplasms. (2016, January 1). Clinical Cancer Research. 22(1):79-85.

Kulke MH, O'Dorisio T, Phan A, et al. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. (2014, October). Endocrine-Related Cancer. 21(5):705-714. Extrait de: http://erc.endocrinology-journals.org/content/21/5/705.long.

Manoly I, McAnelly SL, Sriskandarajah S, McLaughlin KE. Prognosis of patients with carcinoid heart disease after valvular surgery. (2014, August). Interactive Cardiovascular and Thoracic Surgery. 19(2):302-305. Extrait de: http://icvts.oxfordjournals.org/content/19/2/302.long.

Mitry E, Walter T, Baudin E, et al. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial): a phase II non-randomised trial. (2014, December). European Journal of Cancer. 50(18):3107-3115.

Modlin IM, Frilling A, Salem RR, et al. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies. (2016, January). Surgery. 159(1):336-347.

Modlin IM, Kidd M, Bodei L, Drozdov I, Aslanian H. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. (2015, August). American Journal of Gastroenterology. 110(8):1223-1232.

Modlin IM, Oberg K, Taylor A, Drozdov I, Bodei L, Kidd M. Neuroendocrine tumor biomarkers: current status and perspectives. (2014). Neuroendocrinology. 100(4):265-277. Extrait de: http://www.karger.com/Article/FullText/368363.

Oberg K, Modlin IM, De Herder W, et al. Consensus on biomarkers for neuroendocrine tumour disease. (2015, September). Lancet Oncology. 16(9):e435-446.

Pavel M, Horsch D, Caplin M, et al. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. (2015, April). Journal of Clinical Endocrinology and Metabolism. 100(4):1511-1519. Extrait de: http://press.endocrine.org/doi/10.1210/jc.2014-2247?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed.

Sadowski SM, Neychev V, Millo C, et al. Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. (2016, February 20). Journal of Clinical Oncology. 34(6):588-596.

Wolin EM, Jarzab B, Eriksson B, et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. (2015, September 3). Drug Design, Development and Therapy. 9:5075-5086. Extrait de: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562767/.

Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. (2016, March 5). Lancet. 387(10022):968-977.